Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

01-06-2012 | Original Paper

Psychotropic Medications in Autism: Practical Considerations for Parents

Auteurs: Edwin D. Williamson, Andres Martin

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 6/2012

Abstract

Medications are widely prescribed in children with autism spectrum disorders. Most commonly these medications are used to decrease symptoms that fall under three main clusters: irritability, ADHD-like symptoms, and repetitive behaviors. In this guide we introduce basic approaches to medications in children with autism and review the scientific evidence in each symptom cluster.

vorige artikel Evidence-Based Behavioral Interventions for Repetitive Behaviors in Autism

volgende artikel The Implications of Social Neuroscience for Social Disability

Aman, M. G., McDougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., Wagner, A. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. Journal of American Academy of Child and Adolescent Psychiatry.

Belsito, K. M., Law, P. A., Kirk, K. S., Landa, R. J., & Zimmerman, A. W. (2001). Lamotrigine therapy for autistic disorder: A randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders, 31(2), 175–181.PubMedCrossRef

Correll, C. U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J. M., & Malhotra, A. K. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Journal of American Medical Association, 302(16), 1765–1773.CrossRef

Hellings, J. A., Weckbaugh, M., Nickel, E. J., Cain, S. E., Zarcone, J. R., Reese, R. M., et al. (2005). A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 15(4), 682–692.PubMedCrossRef

Hollander, E., Chaplin, W., Soorya, L., Wasserman, S., Novotny, S., Rusoff, J., Anagnostou, E. (2009). Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. Advance online publication, December 9, 2009.

King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., et al. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Archives of General Psychiatry, 66(6), 583–590.PubMedCrossRef

Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of American Academy of Child and Adolescent Psychiatry, 48(11), 1110–1119.CrossRef

McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., et al. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314–321.PubMedCrossRef

McDougle, C. J., Stigler, K. A., & Posey, D. J. (2003). Treatment of aggression in children and adolescents with autism and conduct disorder. Journal of Clinical Psychiatry, 64(Suppl 4), 16–25.PubMed

Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., et al. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatricsm, 124(6), 1533–1540.CrossRef

Research Units on Pediatric Psychopharmacology Autism Network. (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62(11), 1266–1274.CrossRef

Scahill, L., Aman, M. G., McDougle, C. J., McCracken, J. T., Tierney, E., Dziura, J., et al. (2006). A prospective open trial of guanfacine in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 589–598.PubMedCrossRef

Singh, J., Illes, J., Lazzeroni, L., & Hallmayer, J. (2009). Trends in US autism research funding. Journal of Autism and Developmental Disorders, 39(5), 788–795.PubMedCrossRef

Stigler, K. A., Desmond, L. A., Posey, D. J., Wiegand, R. E., & McDougle, C. J. (2004). A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 14, 49–56.PubMedCrossRef

Williams, K. W., Wray, J. J., & Wheeler, D. M. (2005). Intravenous secretion for autism spectrum disorder. Cochrane Database Systematic Reviews, 3, CD003495.

Titel: Psychotropic Medications in Autism: Practical Considerations for Parents
Auteurs: Edwin D. Williamson
Andres Martin
Publicatiedatum: 01-06-2012
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 6/2012
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-010-1144-2

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 6/2012

Visual Attention and Autistic Behavior in Infants with Fragile X Syndrome

Is Long-Term Prognosis for Pervasive Developmental Disorder Not Otherwise Specified Different from Prognosis for Autistic Disorder? Findings from a 30-Year Follow-Up Study

Characteristics and Quality of Autism Websites

G. J. Derbyshire: Stand up for Autism: A Boy, a Dog, and a Prescription for Laughter

Valence Scaling of Dynamic Facial Expressions is Altered in High-Functioning Subjects with Autism Spectrum Disorders: an fMRI Study

Applying Technology to Visually Support Language and Communication in Individuals with Autism Spectrum Disorders